CHM 0.00% 2.1¢ chimeric therapeutics limited

Ann: Clinical milestones for 2024 & 2023 successes highlighted, page-15

  1. 764 Posts.
    lightbulb Created with Sketch. 525
    https://investors.bms.com/iframes/press-releases/press-release-details/2024/FDA-Advisory-Committee-Votes-in-Favor-of-Bristol-Myers-Squibbs-and-2seventy-bios-Abecma-for-Triple-Class-Exposed-Multiple-Myeloma-in-Earlier-Lines-of-Therapy/default.aspx
    https://myelomaresearchnews.com/news/car-t-cell-therapy-farvykti-favored-earlier-multiple-myeloma-treatment/

    The ODAC advisory committee has voted in favour for 2 CAR-T therapies in earlier lines of treatment for multiple myeloma. Voting was convincing, bodes well for future CAR-T therapies in earlier lines of treatment.


 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
(20min delay)
Last
2.1¢
Change
0.000(0.00%)
Mkt cap ! $18.39M
Open High Low Value Volume
2.1¢ 2.1¢ 2.1¢ $9.959K 474.2K

Buyers (Bids)

No. Vol. Price($)
6 1322541 2.0¢
 

Sellers (Offers)

Price($) Vol. No.
2.1¢ 32523 1
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
CHM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.